Pharmacogenomics Corner

Back to articles

What do drug labels say about pharmacogenomic tests?

KEY POINT

A review of 119 FDA-approved drug labels with biomarker information indicated wide variability in the scope, presentation, and level of supporting evidence for pharmacogenomic testing. More than half of drug–biomarker recommendations related to adverse events and approximately one-third to drug efficacy. Oncology drugs were more likely to have evidence of clinical utility supporting a pharmacogenomic test than were other agents.